Ranbaxy, Teva Agree To New York Anti-Competition Settlement
This article was originally published in PharmAsia News
Executive Summary
Ranbaxy Laboratories and Teva Pharmaceutical Industries have reached a settlement in a case that accused them of colluding to restrict competition for their generic drugs, according to New York's attorney general.